SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Recht A, Bartelink H, Fourquet A, et al. Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol. 1998; 16: 28862889.
  • 2
    Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19: 15391569.
  • 3
    Truong PT, Olivotto IA, Whelan TJ, et al. Steering Committee on Clinical Practice Guidelines for the care and treatment of breast cancer. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional postmastectomy radiotherapy. CMAJ. 2004; 170: 12631273.
  • 4
    Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997; 337: 949955.
  • 5
    Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group (DBCG) 82c randomised trial. Lancet. 1999; 353: 16411648.
  • 6
    Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997; 337: 956962.
  • 7
    Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000; 18: 28172827.
  • 8
    Katz A, Buchholz TA, Thames H, et al. Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation. Int J Radiat Oncol Biol Phys. 2001; 50: 397403.
  • 9
    Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999; 17: 16891700.
  • 10
    Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003; 21: 12051213.
  • 11
    Voordeckers M, Vinh-Hung V, Van de Steene J, Lamote J, Storme G. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004; 70: 225230.
  • 12
    van der Wal BCH, Butzelaar RMJM, van der Meij S, Boermeester MA. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in Stage I and II breast cancer. Eur J Surg Oncol. 2002; 28: 481489.
  • 13
    Megale Costa LJ, Soares HP, Gaspar HA, et al. Ratio between positive lymph nodes and total dissected axillary lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol. 2004; 27: 304306.
  • 14
    Whelan TJ, Julian J, Wright J, et al. Does locoregional radiotherapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000; 18: 12201229.
  • 15
    The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: axillary dissection. CMAJ. 1998; 158(3 Suppl ): S22S26.
  • 16
    Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer. 1992; 28: 14151418.
  • 17
    Danforth DN Jr., Findlay PA, McDonald HD, et al. Complete axillary lymph node dissection for Stage I–II carcinoma of the breast. J Clin Oncol. 1986; 4: 655662.
  • 18
    Iyer RV, Hanlon A, Fowble B, et al. Accuracy of the extent of axillary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined. Int J Radiat Oncol Biol Phys. 2000; 47: 11771183.
  • 19
    Camp RL, Rimm EB, Rimm DL. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer. 2000; 88: 108113.
  • 20
    Mersin H, Yildirim E, Bulut H, et al. The prognostic significance of total lymph node number in patients with axillary lymph node-negative breast cancer. Eur J Surg Oncol. 2003; 29: 132138.
  • 21
    Saha S, Farrar WB, Young DC, et al. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol. 2000; 73: 134137.
  • 22
    Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy and total mastectomy followed by irradiation. N Engl J Med. 2002; 347: 567575.
  • 23
    Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349: 546553.
  • 24
    GreenFL, PageDL, FlemingID, et al., editors. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002.
  • 25
    Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002; 20: 36283636.
  • 26
    Krag DN, Julian TB, Harlow SP, et al. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinel lymph node dissection: a description of the trial. Ann Surg Oncol. 2004; 11(3 Suppl ): 208S210S.